Abstract: Idiopathic Pulmonary Fibrosis (IPF) and Tuberculosis (TB) are both complicated diseases and gradually increasing their incidence rates worldwide. Some population-based studies reported that ...
While the vaccines are products of private sector innovation, their evaluation has been firmly anchored in public science, ...
A new national cohort study provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The ...
Enhanced Bacteriological Response: The study reveals that high-dose rifampicin increased the 8-week sputum conversion rate ...
While tuberculosis spread is not significant nationally, lack of awareness of the latent form of the condition raises ...
A phase 3 trial of two tuberculosis vaccines shows limited overall protection but meaningful efficacy against extrapulmonary ...
BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes ...
Personalized cancer vaccines are showing real clinical results, with melanoma patients on the mRNA-4157/pembrolizumab ...
A phase-3 trial published in The British Medical Journal finds two new TB vaccines, VPM1002 and Immuvac, safe for use in India but not effective against all forms of tuberculosis, though they may help ...
Two new tuberculosis vaccines have been found to be safe for use in both adults and children in India, but may not offer ...
New TB vaccines show safety but limited protection against all infection forms, particularly for adolescents and adults, phase-3 study reveals.
The two new tuberculosis vaccines could be safe for use in adults and children in India but may not provide protection against all forms of the infectious bacterial disease, according to phase-3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results